James J Goedert1, Maureen P Martin2, Francesco Vitale3, Carmela Lauria4, Denise Whitby5, Ying Qi2, Xiaojiang Gao2, Mary Carrington2. 1. Division of Cancer Epidemiology and Genetics, Division of Cancer Epidemiology and Genetics, National Cancer Institute. 2. Cancer and Inflammation Program, Laboratory of Experimental Immunology Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts. 3. Dipartimento di Igiene e Microbiologia Giuseppe D'Alessandro, Universitá degli Studi di Palermo. 4. Lega Italiana per la Lotta Contro i Tumori-Sez Ragusa, Italy. 5. Viral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Maryland.
Abstract
BACKGROUND: Kaposi sarcoma (KS) is a complication of KS-associated herpesvirus (KSHV) infection. Other oncogenic viral infections and malignancies are associated with certain HLA alleles and their natural killer (NK) cell immunoglobulin-like receptor (KIR) ligands. We tested whether HLA-KIR influences the risk of KSHV infection or KS. METHODS: In population-based case-control studies, we compared HLA class I and KIR gene frequencies in 250 classic (non-AIDS) KS cases, 280 KSHV-seropositive controls, and 576 KSHV-seronegative controls composing discovery and validation cohorts. Logistic regression was used to calculate sex- and age-adjusted odds ratios (ORs) and 95% confidence intervals. RESULTS: In both the discovery and validation cohorts, KS was associated with HLA-A*11:01 (adjusted OR for the combined cohorts, 0.4; P = .002) and HLA-C*07:01 (adjusted OR, 1.6; P = .002). Consistent associations across cohorts were also observed with activating KIR3DS1 plus HLA-B Bw4-80I and homozygosity for HLA-C group 1. With KIR3DS1 plus HLA-B Bw4-80I, the KSHV seroprevalence was 40% lower (adjusted OR for the combined cohorts, 0.6; P = .01), but the KS risk was 2-fold higher (adjusted OR, 2.1; P = .002). Similarly, the KSHV seroprevalence was 40% lower (adjusted OR, 0.6; P = .01) but the KS risk 80% higher with HLA-C group 1 homozygosity (adjusted OR, 1.8; P = .005). CONCLUSIONS: KIR-mediated NK cell activation may decrease then risk of KSHV infection but enhance KSHV dissemination and progression to KS if infection occurs. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Kaposi sarcoma (KS) is a complication of KS-associated herpesvirus (KSHV) infection. Other oncogenic viral infections and malignancies are associated with certain HLA alleles and their natural killer (NK) cell immunoglobulin-like receptor (KIR) ligands. We tested whether HLA-KIR influences the risk of KSHV infection or KS. METHODS: In population-based case-control studies, we compared HLA class I and KIR gene frequencies in 250 classic (non-AIDS) KS cases, 280 KSHV-seropositive controls, and 576 KSHV-seronegative controls composing discovery and validation cohorts. Logistic regression was used to calculate sex- and age-adjusted odds ratios (ORs) and 95% confidence intervals. RESULTS: In both the discovery and validation cohorts, KS was associated with HLA-A*11:01 (adjusted OR for the combined cohorts, 0.4; P = .002) and HLA-C*07:01 (adjusted OR, 1.6; P = .002). Consistent associations across cohorts were also observed with activating KIR3DS1 plus HLA-B Bw4-80I and homozygosity for HLA-C group 1. With KIR3DS1 plus HLA-B Bw4-80I, the KSHV seroprevalence was 40% lower (adjusted OR for the combined cohorts, 0.6; P = .01), but the KS risk was 2-fold higher (adjusted OR, 2.1; P = .002). Similarly, the KSHV seroprevalence was 40% lower (adjusted OR, 0.6; P = .01) but the KS risk 80% higher with HLA-C group 1 homozygosity (adjusted OR, 1.8; P = .005). CONCLUSIONS:KIR-mediated NK cell activation may decrease then risk of KSHV infection but enhance KSHV dissemination and progression to KS if infection occurs. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
Italy; Kaposi sarcoma; case-control study; human genetics; human leukocyte antigens; major histocompatibility complex; natural killer–cell immunoglobulin-like receptors
Authors: Nafisa-Katrin Seich Al Basatena; Aidan Macnamara; Alison M Vine; Chloe L Thio; Jacquie Astemborski; Koichiro Usuku; Mitsuhiro Osame; Gregory D Kirk; Sharyne M Donfield; James J Goedert; Charles R M Bangham; Mary Carrington; Salim I Khakoo; Becca Asquith Journal: PLoS Pathog Date: 2011-10-13 Impact factor: 6.823
Authors: Elena M Cornejo Castro; Brian J Morrison; Vickie A Marshall; Nazzarena Labo; Wendell J Miley; Nathan Clements; George Nelson; Paul Ndom; Kristen Stolka; Jennifer J Hemingway-Foday; Mahamat Abassora; Xiaojiang Gao; Jennifer S Smith; Mary Carrington; Denise Whitby Journal: Genes Immun Date: 2019-05-20 Impact factor: 2.676
Authors: Melissa J Blumenthal; Charlotte Schutz; Graeme Meintjes; Zainab Mohamed; Marc Mendelson; Jon M Ambler; Denise Whitby; Romel D Mackelprang; Sinead Carse; Arieh A Katz; Georgia Schäfer Journal: Cancer Epidemiol Date: 2018-08-31 Impact factor: 2.984
Authors: Vickie A Marshall; Nazzarena Labo; Joanna Sztuba-Solinska; Elena M Cornejo Castro; Karen Aleman; Kathleen M Wyvill; Lynne McNamara; Stuart F J Le Grice; Robert Yarchoan; Thomas S Uldrick; Patrick MacPhail; Mark N Polizzotto; Denise Whitby Journal: Oncotarget Date: 2018-11-09
Authors: Robert Newton; Denise Whitby; Inês Barroso; Neneh Sallah; Wendell Miley; Nazzarena Labo; Tommy Carstensen; Segun Fatumo; Deepti Gurdasani; Martin O Pollard; Alexander T Dilthey; Alexander J Mentzer; Vickie Marshall; Elena M Cornejo Castro; Cristina Pomilla; Elizabeth H Young; Gershim Asiki; Martin L Hibberd; Manjinder Sandhu; Paul Kellam Journal: Nat Commun Date: 2020-07-31 Impact factor: 14.919